(0.34%) 5 117.20 points
(0.33%) 38 366 points
(0.38%) 15 988 points
(-0.95%) $83.05
(5.56%) $2.03
(0.35%) $2 355.30
(0.46%) $27.66
(4.06%) $959.55
(-0.26%) $0.932
(-0.41%) $10.98
(-0.57%) $0.796
(1.69%) $93.43
@ $1.954
発行日: 14 2月 2024 @ 23:32
リターン: -25.54%
前回のシグナル: 2月 8 - 06:00
前回のシグナル:
リターン: 1.24 %
Live Chart Being Loaded With Signals
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers...
Stats | |
---|---|
本日の出来高 | 247 278 |
平均出来高 | 430 161 |
時価総額 | 50.91M |
EPS | $0 ( 2024-04-04 ) |
次の収益日 | ( $-0.370 ) 2024-05-20 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.460 |
ATR14 | $0.00400 (0.27%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-20 | Fortress Biotech, Inc. | Buy | 193 905 | COMMON STOCK, PAR VALUE $0.0001 |
2024-03-12 | Amit Sharma | Sell | 0 | Common Stock (Restricted) |
2024-02-28 | Oliviero James F Iii | Sell | 5 894 | COMMON STOCK |
2024-02-28 | Oliviero James F Iii | Sell | 9 056 | COMMON STOCK |
2024-02-28 | Gray William Garrett | Sell | 2 035 | Common Stock |
INSIDER POWER |
---|
82.65 |
Last 98 transactions |
Buy: 5 337 828 | Sell: 1 367 663 |
ボリューム 相関
Checkpoint Therapeutics 相関
10 最も負の相関 | |
---|---|
NETE | -0.95 |
MMAC | -0.934 |
STAY | -0.927 |
BNIXU | -0.92 |
CCRC | -0.92 |
NVCN | -0.912 |
DSPG | -0.911 |
XM | -0.909 |
FEXD | -0.901 |
AVEO | -0.896 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Checkpoint Therapeutics 相関 - 通貨/商品
Checkpoint Therapeutics 財務諸表
Annual | 2023 |
収益: | $103 000 |
総利益: | $-43.46M (-42 197.09 %) |
EPS: | $-2.77 |
FY | 2023 |
収益: | $103 000 |
総利益: | $-43.46M (-42 197.09 %) |
EPS: | $-2.77 |
FY | 2022 |
収益: | $192 000 |
総利益: | $-49.63M (-25 850.52 %) |
EPS: | $-7.57 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-10.15 |
Financial Reports:
No articles found.
Checkpoint Therapeutics
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。